Enterocolitis - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2017, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Enterocolitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Enterocolitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Enterocolitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Enterocolitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Enterocolitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Enterocolitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Enterocolitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Enterocolitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Enterocolitis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Enterocolitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Enterocolitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Enterocolitis - Overview 6
Enterocolitis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Enterocolitis - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 17
Enterocolitis - Companies Involved in Therapeutics Development 19
AvidBiotics Corp 19
Infant Bacterial Therapeutics AB 19
Leadiant Biosciences Inc 20
Enterocolitis - Drug Profiles 21
AvR-2V10 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
C-34 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
IBP-9414 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
melatonin - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
NRG-4 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules for Necrotizing Enterocolitis - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
STP-206 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Enterocolitis - Dormant Projects 31
Enterocolitis - Product Development Milestones 32
Featured News & Press Releases 32
Sep 28, 2017: European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT's lead product 32
Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups 32
Jan 24, 2017: Last patient enrolled in IBT's Phase 2 study 32
Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study 33
Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial 33
Mar 31, 2016: IBT receives Rare Pediatric Disease Designation from FDA for drug candidate 33
Jan 08, 2016: BioGaia's subsidiary IBT has US IND open and Swedish CTA approved for clinical study 33
Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants 34
Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics 34
Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia 35
Feb 23, 2015: BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe 35
Feb 21, 2014: FDA approves orphan drug designation for IBP-9414 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables

Number of Products under Development for Enterocolitis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 16
Number of Products by Stage and Molecule Type, H2 2017 18
Enterocolitis - Pipeline by AvidBiotics Corp, H2 2017 19
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H2 2017 19
Enterocolitis - Pipeline by Leadiant Biosciences Inc, H2 2017 20
Enterocolitis - Dormant Projects, H2 2017 31